Chemotherapy for patients with metastatic carcinoma of unknown primary site

Carcinoma of an Unknown Primary Site

Volumn , Issue , 2006, Pages 93-103

  Greco, F Anthony ^a   Culine, Stephane ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58549091359     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (40)

1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia, Lippincott: Williams and Wilkens, 2001:2537-2560.
2. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39:1990.
3. Wagener DJT, de Muelder PHM, Burghouts JT, et al. Phase II trial of cisplatin for adenocarcinoma of unknown primary site. Eur J Cancer 1991; 27:755-757.
4. Casciato DA. Metastasis of unknown origin. In: Haskell C. ed. Cancer Treatment. 4th ed. Philadelphia: W.B. Saunders Company, 1995:1128-1148.
5. Milliken ST, Tattersall MHN, Woods RL, et al. Metastatic adenocarcinoma of unknown primary site: a randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987; 23:1645-1648.
6. McKeen E, Smith F, Haidak D, et al. Fluorouracil, adriamycin and mitomycin-C for adenocarcinoma of unknown origin [abstr]. Proc Am Assoc Cancer Res 1980; 21:358.
7. Woods RL, Fox RM, Tattersall MHN, et al. Metastatic adenocarcinoma of unknown primary: a randomized study of two combination-chemotherapy regimens. N Engl J Med 1980; 303:87-89.
8. Eagan RT, Thermean TM, Rubin J, et al. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. Am Clin Oncol 1987; 10:82-85.
9. Goldberg RM, Smith FP, Ueno W, et al. Fluorouracil, adriamycin and mito-mycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986; 4:395-399.
10. Kambhu I, Kelsen D, Niedzwiecki D, et al. Phase II trial of mitomycin-C, vindesine, and adriamycin and predictive variables in the treatment of patients with adenocarcinoma of unknown primary site [abstr]. Proc Am Assoc Cancer Res 1986; 27:734.
11. Flore JJ, Kelsen DP, Gralla RJ, et al. Adenocarcinoma of unknown primary origin. Treatment with vindesine and doxorubicin. Cancer Treat Rep 1985; 69:591-594.
12. Valentine J, Rosenthal S, Arseneau JC. Combination chemotherapy for adeno-carcinoma of unknown primary origin. Cancer Clin Trials 1979; 2:265-268.
13. Rudnick S, Tremont S, Staab E, et al. Evaluation and therapy of adenocarci-noma of unknown primary [abstr]. Proc Am Soc Clin Oncol 1981; 1:379.
14. Sulkes A, Uziely B, Isacson R, et al. Combination chemotherapy in metastatic tumors unknown origin. Ist J Med Sci 1988; 24:604-610.
15. Van der Gaast A, Verweij J, Planting AST, et al. 5-Fluorouracil, doxorubicin, and mitomycin c (FAM) combination chemotherapy for metastatic adenocarci-noma of unknown primary. Eur J Cancer Clin Oncol 1988; 24:765-768.
16. TreatJ, FalchukSC, TremblayC, etal. Phase II trial ofmethotrexate-FAM inade-nocarcinoma of unknown primary. Eur J Cancer Clin Oncol 1989; 25:1053-1055.
17. Nole F, Colleoni M, Buzzoni R, et al. Fluorouracil plus folinic acid in meta-static adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. Tumori 1993; 79:116-118.
18. Falkson CI, Cohen GL. Mitomycin-c, epirubicin and cisplatin versus mitomycin-c alone as therapy for carcinoma of unknown primary origin. Oncology 1998; 55:116.
19. Hainsworth JD, Erland JB, Kalman CA, et al. Carcinoma ofunknown primary site: treatment with one-hour paclitaxel, carboplatin and extended schedule etoposide. J Clin Oncol 1997; 15:2385-2393.
20. Greco FA, Gray J, Burris HA, et al. Taxane-based chemotherapy with carcinoma of unknown primary site. Cancer J 2001; 7:203-212.
21. Greco FA, Erland JB, Morrissey LH, et al. Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000; 11:211-215.
22. Greco FA, Burris HA, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20:1651-1656.
23. Greco FA, Hainsworth JD, Yardley DA, et al. Sequential paclitaxel/carbopla-tin/etoposide followed by irinotecan/gemcitabine for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2002; 21:161a.
24. Culine S, Fabbro M, Ychou M, et al. Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy. Ann Oncol 1999; 10:569-575.
25. Culine S, Fabbro M, Ychou M, et al. Alternative bimonthly cycles of doxoru-bicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 2002; 94:840-846.
26. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004; 100:1257-1261.
27. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21:3479-3482.
28. Altman E, Cadman E. An analysis of 1,539 patients with cancer of unknown primary site. Cancer 1986; 57:120-124.
29. Hess KR, Abbruzzese MC, Lenzi R, et al. Classification and regression free analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999; 5:3403-3410.
30. Holmes FT, Fouts TL. Metastatic cancer of unknown primary site. Cancer 1970; 26:816-820.
31. Krementz ET, Cerise EJ, Foster DC, et al. Metastases of undetermined source. Curr Probl Cancer 1979; 4:1-37.
32. Markman M. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at the Johns Hopkins Hospital from 1965-1979. Med Ped Oncol 1982; 10:569-574.
33. Moertel CG, Reitmeier RJ, Schutt AJ, et al. Treatment of the patient with adenocarcinoma of unknown primary site. Cancer 1972; 30:1469-1472.
34. Van de Wouw AJ, Janssen-Heijnen MLC, Coebergh JWW, et al. Epidemiology of unknown primary tumors; incidence and population-based survival of 1285 patients in Southeast Netherland 1984-1992. Eur J Cancer 2002; 38:409-413.
35. Levi F, Te VC, Erler G, et al. Epidemiology of unknown primary tumors. Eur J Cancer 2002; 38:1810-1812.
36. Muir C. Cancer of unknown primary site. Cancer 1995; 75:353.
37. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study. J Clin Oncol 2000; 18:3101-3107.
38. Lastra E, Munoz A, Rubio I, et al. Paclitaxel, carboplatin, and oral etoposide in the treatment of patients with carcinoma of unknown primary site. Proc Am Soc Clin Oncol 2000; 19:579a.
39. Mukai H, Watanabe T, Ando M, et al. A safety and efficacy trial of docetaxel and cisplatin in patients with cancer of unknown primary. Proc Am Soc Clin Oncol 2003; 22:646.
40. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 7th ed. Philadelphia, Lippincott: Williams and Wilkins, 2005:2213-2236.